# US 2023/0054466 A1 · Compositions and methods for treatment of cancers harboring an h3k27m mutation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054466 A1
- Document ID: US20230054466A1
- Status: Published application
- Kind: A1
- Application number: 17/815,056
- Filed: 2022-07-26
- Published: 2023-02-23
- Earliest claimed: 2017-07-12
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Michelle Monje-Deisseroth; Robbie Majzner; Crystal Mackall; Christopher Mount
- Web page: https://patentgrep.com/patent/US20230054466A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4258: {Gangliosides, e.g. GM2, GD2 or GD3}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/3084: {against tumour-associated gangliosides}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2319/03: containing a transmembrane segment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3 K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method of killing cancer cells in vitro comprising contacting the cancer cells with an effective amount of immune cells genetically modified to express a chimeric antigen receptor (CAR) specific for ganglioside GD2 (GD2),
wherein the cancer cells are characterized by a histone H3 K27M (H3K27M) mutation.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cancer cells are isolated from a subject.

### Claim 26 (depends on 24)

The method of claim 24, wherein the cancer cells are derived from a glioma.

### Claim 27 (depends on 26)

The method of claim 26, wherein the glioma is diffuse intrinsic pontine glioma (DIPG) or diffuse midline glioma.

### Claim 28 (depends on 24)

The method of claim 24, wherein the immune cells are T cells.

### Claim 29 (depends on 24)

The method of claim 24, wherein the immune cells are natural killer (NK) T cells.

### Claim 30 (depends on 24)

The method of claim 24, wherein the chimeric antigen receptor (CAR) specific for GD2 comprises an antigen binding domain of an antibody selected from the group consisting of 14G2a, ch14.18, hu14.18K322A, m3F8, hu3F8-IgG1, hu3F8-IgG4, HM3F8, and DMAb-20.

### Claim 31 (depends on 30)

The method of claim 30, wherein the antigen binding domain is a single-chain variable fragment (scFv).

### Claim 32 (depends on 30)

The method of claim 30, wherein the chimeric antigen receptor (CAR) specific for GD2 further comprises a T cell transmembrane domain, a T cell receptor signaling domain, and/or at least one co-stimulatory domain.

### Claim 33 (depends on 32)

The method of claim 32, wherein the co-stimulatory domain comprises part or all of one or more of CD28, OX40/CD134, 4-1BB/CD137/TNFRSF9, FcERIγ, ICOS/CD278, ILRB/CD122, IL-2RG/CD132, and CD40.

### Claim 34 (depends on 24)

The method of claim 24, wherein the chimeric antigen receptor (CAR) specific for GD2 comprises an antigen binding domain containing heavy and light chain variable regions (scFv) that bind with specificity to the GD2 epitope: GalNAcβ1-4(NeuAcα2-8NeuAcα2-3)Gal.

### Claim 35 (depends on 24)

The method of claim 24, wherein the CAR comprises the 14G2a scFv.

### Claim 36

A method comprising:
a) obtaining a biological sample comprising cancer cells from a patient;
b) determining presence of an H3K27M mutation within the cancer cells; and
c) contacting the cancer cells immune cells genetically modified to express a chimeric antigen receptor (CAR) specific for ganglioside GD2 (GD2).

### Claim 37 (depends on 36)

The method of claim 36, wherein the cancer is selected from the group consisting of diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma.

### Claim 38 (depends on 36)

The method of claim 36, wherein the contacting kills the cancer cells.

### Claim 39 (depends on 36)

The method of claim 36, wherein the contacting induces cytokine generation.

### Claim 40 (depends on 36)

The method of claim 36, further comprising determining an effective amount of immune cells genetically modified to express a CAR specific for GD2 to achieve potent cell lysis.
